Tag: femoropopliteal
Endovascular showdown: CX 2024 sets the stage for BASIL-3 first-time data...
At the Charing Cross (CX) Symposium 2024 (23–25 April, London, UK), Andrew Bradbury (University of Birmingham, Birmingham, UK) and the BASIL-3 team of triallists...
AVS’ pulsatile IVL technology attracts an additional US$8.8 million to close...
AVS, an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its pulsatile intravascular lithotripsy (PIVL) therapy, has...
Endologix submits premarket approval application to FDA for Detour system
Endologix has announced the submission of a premarket approval (PMA) application requesting approval for the Detour system to the US Food and Drug Administration...
SIRONA head-to-head randomised trial achieves 50% enrolment
Concept Medical recently announced that the SIRONA randomised controlled trial (RCT)—a head-to-head comparison of sirolimus versus paclitaxel drug-eluting balloon angioplasty in the femoropopliteal artery—has...
Surgeons must stay skilled in femorotibial/pedal bypass surgery, PVI audience hears
At Paris Vascular Insights (PVI) 2021 (21–23 October, Paris, France), Peter Schneider (University of California San Francisco, San Francisco, USA) emphasised the need for...
Femoropopliteal bypass shows reintervention benefit over endovascular therapy for advanced premature...
Femoropopliteal bypass is associated with decreased reinterventions at one year compared to endovascular therapy in patients with advanced premature peripheral arterial disease (PAD). This...
REALITY study “sets new benchmark” for assessment of claudicants with severe...
Krishna Rocha-Singh (Springfield, USA) speaks to Vascular News about his presentation at VIVA20 (Vascular Interventional Advances; 6–7 November 2020; virtual) on the REALITY study,...
Veryan Medical announces US launch and first commercial implant of BioMimics...
Veryan Medical recently announced the US launch and first commercial implant in the USA of the BioMimics 3D vascular stent system.
According to a press...
Customising therapy in femoropopliteal revascularisation
Gary Ansel (Columbus, USA) tells Vascular News at VEITHSymposium 2018 about how drug-based therapies have become a mainstay in femoropopliteal revascularisation and how interventionalists...
New JAMA analysis with short follow-up finds “an association of survival”...
A recent US-wide, multicentre analysis has found no evidence of increased all-cause mortality associated with the use of paclitaxel-coated devices compared with non-drug-coated devices...
Patient-level survival analysis demonstrates no link between paclitaxel dose and mortality...
New data on the IN.PACT Admiral drug-coated balloon (DCB; Medtronic) in patients with peripheral arterial disease (PAD) in the superficial femoral (SFA) and popliteal...
IN.PACT independent patient-level meta-analysis shows no correlation between paclitaxel exposure and...
A renowned panel, moderated by Dierk Scheinert (Leipzig, Germany), comprising Peter Schneider (Honolulu, USA), John Laird (St Helena, USA) and Thomas Zeller (Bad Krozingen,...
